| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2014193930 |
| Title |
Method for Inhibiting Ezh2 Expression In Breast Cancer Cells. |
| Abstract |
The present invention is directed to a method for inhibiting the overexpression of EZH2 in breast cancer cells. The method comprises administering to breast cancer cells an effective amount of YC-1 (3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole), YC-1-succinate (succinic acid mono-[5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl] ester), or a pharmaceutically acceptable salt thereof. The present invention is also directed to treating breast cancer comprising administering to a subject an effective amount of YC-1-succinate. |
| Applicant(s) |
Yung Shin Pharm. Ind. Co., Ltd |
| Representative Drug(s) |
D0L1TA |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2013158892 |
| Title |
Thioredoxin Protein Inhibitors and Uses Thereof. |
| Abstract |
A method of treating a fungal infection in a subject including administering to the subject a therapeutically effective amount of a thioredoxin protein inhibitor to treat the fungal infection in the subject. |
| Applicant(s) |
Case Western Reserve University |
| Representative Drug(s) |
D0M0UE |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2011117568 |
| Title |
Compounds Targeting The Vegf and/or Hif Pathway Such As Sorafenib or Vatalanib for Use In The Treatment of Otitis Media. |
| Abstract |
The present invention provides a compound which targets the VEGF and/or HIF pathways for use in the treatment and/or prevention of otitis media in a subject. The invention also provides a pharmaceutical composition comprising such a compound and a method for treating and/or preventing otitis media in a subject which comprises the step of administering such a compound or pharmaceutical composition to the subject. |
| Applicant(s) |
Medical Research Council |
| Representative Drug(s) |
D03OYJ |
Drug Info
|
N.A. |
[1] |
| Patent ID |
WO2012152295 |
| Title |
Pyrazolyl Compounds for Use In Reversing Reactive Gliosis. |
| Abstract |
The present invention refers to a compound which is a pyrazolyl compound for use as a medicament in a neurodegenerative disease or disorder, preferably reactive gliosis. Also, a pyrazolyl compound that is 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1) for use as a medicament in a disease or disorder, preferably for the treatment, reversal or the attenuation of reactive gliosis, and/or reactive gliosis directly or indirectly associated with an eye disease, disease of the retina, or retinal disorder.. Further, the invention discloses pharmaceutical compositions thereof and a method for treating a neurodegenerative disorder, preferably reactive gliosis, comprising administering to a subject in need thereof an effective amount of such compound or pharmaceutical composition. |
| Applicant(s) |
King Faisal Specialist Hospital and Research Center |
